Le Lézard
Classified in: Health, Science and technology
Subject: PARTNERSHIPS

Topstone Research Joins the Medrio Partner Program, Further Aligning the Two Companies


SAN FRANCISCO, CA--(Marketwired - June 13, 2017) - Topstone Research, a full-service contract research organization (CRO) offering a full range of clinical research services, has joined the Partner Program at Medrio, a Software as a Service (SaaS) company providing electronic data capture (EDC) and eSource to clinical trials. Topstone Research is a well-established Medrio customer, and now as a Medrio Partner, they will be able to take advantage of comprehensive training and support by Medrio's staff, recommendations to clinical trial sponsors, and other services. Their decision to join the Partner Program signifies a desire to officially establish Medrio as one of their preferred eClinical providers.

Since Topstone began using Medrio, they have used the system to successfully set up numerous databases for clinical trials of all phases. The Topstone data management team appreciates the various functionalities offered in the Medrio system, such as its drag-and-drop interface, the ability to design eCRFs without programming, and the advantages of a completely web-based development environment that doesn't require any software installation.

"At Topstone, we take pride in not just collecting data, but making sure it's precise, targeted, and meaningful. I am pleased to acknowledge that Medrio has played an invaluable role in making sure we meet our goals," said Muhammad Bilal, Senior Director, Clinical Data Management and Biostatistics at Topstone Research. "Their innovative, user-friendly tools have tremendously enhanced our data management operations. By the end of our first year as Medrio users, joining the Partner Program was a logical step."

Mike Novotny, founder and CEO of Medrio, added, "Topstone Research takes on some of the most important therapeutic areas in clinical research today, and being involved in their work has been a thrill. We're honored that they've elected to join our Partner Program, and look forward to a long and fruitful business relationship."

The Medrio Partner Program aligns Medrio's sales, marketing, product, and development resources with trusted CROs and consultancies to deliver superior customer experiences. Partners receive comprehensive training, extensive support by Medrio teams, priority for co-marketing opportunities, and product roadmap insight. In addition, Medrio frequently recommends and introduces CRO Partners to prospective sponsor clients with the goal of cultivating joint opportunities and helping CRO Partners win more business.

About Topstone Research

Topstone Research is a full-service contract research organization (CRO) with an unwavering commitment to quality and service flexibility. They specialize in providing outstanding CRO services from protocol development to clinical study reports and beyond, customized to their clients' requirements and executed with well-designed workflow processes and procedures. Topstone Research's studies follow ICH, GCP, and regulatory agency guidelines, and use controlled and secure computing environments with validated, 21 CFR Part 11-compliant software and systems. Their teams of experts are able to provide unique insights into the research environment, competitive landscape, and patient populations of a variety of therapeutic areas. They support their clients' drug development needs by providing real-time, faster access to data, enabling them to make faster decisions and get their drugs to the market as quickly as possible, all while making patient safety a top priority. For more information, please visit www.topstoneresearch.com.

About Medrio

Medrio offers an integrated eClinical SaaS platform designed to eliminate paper from clinical trials. Medrio's affordable, cloud-based EDC and eSource products allow data managers to build studies in days instead of months with no IT or programming required, offering unprecedented speed, simplicity, and control in database build and data management. Users also have access to a world-class support staff backed by a top-tier customer satisfaction rating. Medrio has served over 2,000 clinical trials of all phases and therapeutic areas, with an emphasis on early-phase studies. The company's software has been used in clinical trials conducted across the globe and submitted to all major regulatory bodies.

For more information, or to schedule an online demonstration or request a free trial, please visit www.medrio.com.


These press releases may also interest you

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...

at 02:30
SOPHiA GENETICS , a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India, is live on the SOPHiA...

at 01:15
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...

at 01:05
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...

3 jui 2024
YOUR LEGAL RIGHTS MAY BE AFFECTED There is a proposed settlement in a class-action lawsuit filed against Pfizer Inc., Pfizer Ireland Pharmaceuticals, Warner-Lambert Company, and Warner-Lambert Company LLC (collectively, "Pfizer") and Ranbaxy Inc.,...



News published on and distributed by: